Screener
PTC Therapeutics PTCT Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:32 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001070081-26-000012
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 3,049,569 | 3,104,080 |
| Stockholders’ deficit: | ||
| Common stock, $0.001 par value. Authorized 250,000,000 shares; issued and outstanding 82,882,024 shares at March 31, 2026. Authorized 250,000,000 shares; issued and outstanding 81,474,366 shares at December 31, 2025. | 81 | 80 |
| Additional paid-in capital | 2,778,026 | 2,748,335 |
| Accumulated other comprehensive income | 8,466 | 10,501 |
| Accumulated deficit | (2,967,038) | (2,964,229) |
| Total stockholders’ deficit | (180,465) | (205,313) |
| Total liabilities and stockholders’ deficit | $2,869,104 | $2,898,767 |
Item 1. Financial Statements (unaudited)
FAQ
- What is PTC Therapeutics's retained earnings?
- PTC Therapeutics (PTCT) reported retained earnings of -$2.97B in Q1 2026.
- How has PTC Therapeutics's retained earnings changed year-over-year?
- PTC Therapeutics's retained earnings decreased by 6.7% year-over-year, from -$2.78B to -$2.97B.
- What is the long-term trend for PTC Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), PTC Therapeutics's retained earnings has grown at a 12.7% compound annual growth rate (CAGR), from -$1.63B to -$2.96B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about PTC Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude